Direct methods for distinction between endogenous and exogenous erythropoietin
Lamon, Séverine, Robinson, Neil and Saugy, Martial 2011, Direct methods for distinction between endogenous and exogenous erythropoietin. In Ghigo, Ezio, Lanfranco, Fabio and Strasburger, Christian J. (ed), Hormone use and abuse by athletes, Springer, New York, N. Y., pp.163-175, doi: 10.1007/978-1-4419-7014-5_17.
Attached Files
Name
Description
MIMEType
Size
Downloads
Title
Direct methods for distinction between endogenous and exogenous erythropoietin
Since the commercialization of the first recombinant human erythropoietin (rhEPO) product (epoetin-a) in 1989 as a treatment for acute anemia, rhEPO detection has represented a continuous challenge for the anti-doping fight. Indeed, it appeared rapidly that this ergogenic hormone would be abused by athletes looking for an artificial performance enhancer. Hemoglobin is one of the principal modulators of aerobic power [1, 2] and, consequently, of performance in endurance sports [3]. By stimulating the red blood cells production, EPO is known to raise hemoglobin concentration in a dose-dependant and predictable way. Therefore, this hormone soon became one of the athletes most popular doping agent. Since 1984, all forms of blood doping in sport have been officially banned. In 1990, the IOC medical commission, which was in charge of the anti-doping regulations, added rhEPO to the list of the prohibited drugs in sports, even if a direct test allowing to detect the molecule became available a decade after only.
Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.